.png){kind=icon}
-
Preserving Billions in Potential Revenue: Actionable Insights from GlobalCODE® Analytics Rescue a Phase III Adaptive Oncology Trial
Case StudiesAug. 13, 2018
In a late stage oncology trial for a drug intended to be marketed in Asia, the Data Safety and Monitoring Board (DSMB) noted an apparent decrease in some patients' white blood cell counts in the new drug treatment arm. The client sought to understand whether the drug was responsible for this effect and, if so, what actions could be taken to improve the drug's safety. Using GlobalCODE®, the client prompted a change to the trial testing schedule and was ultimately able to proceed to a new drug application without a safety exclusion.
In a late stage oncology trial for a drug intended to be marketed in Asia, the Data Safety and Monitoring Board (DSMB) noted an apparent decrease in some patients' white blood cell counts in the new drug treatment arm. The client sought to understand whether the drug was responsible for this effect and, if so, what actions could be taken to improve the drug's safety. Using GlobalCODE®, the client prompted a change to the trial testing schedule and was ultimately able to proceed to a new drug application without a safety exclusion.
